CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $171.71M, lower than 95% of all stocks globally
- FinancialsHigh structural barrier to entry
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
171.71MUSDvs all stocks (USD)
Revenue (TTM)
79.17MUSDvs all stocks (USD)
Profit Margin
-173.02%vs Biotechnology peers
Beta
1.88xvs all stocks
52-Week Change
-53.96%vs all stocks
Market Capitalization
171.71MUSDvs all stocks (USD)
Enterprise Value
368.06MUSDvs all stocks (USD)
Forward P/E
-0.9060xvs Biotechnology peers
Price to Sales (TTM)
2.17xvs Biotechnology peers
Enterprise to Revenue
4.65xvs Biotechnology peers
Enterprise to EBITDA
-3.61xvs Biotechnology peers
Gross Margin
82.66%vs Biotechnology peers
Profit Margin
-173.02%vs Biotechnology peers
Operating Margin
-121.07%vs Biotechnology peers
Return on Assets (TTM)
-22.73%vs Biotechnology peers
Revenue (TTM)
79.17MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.6230USDUpdated Jul 17, 2026Quarterly Revenue Growth
-9.50%vs Biotechnology peers
Gross Profit (TTM)
-20.85MUSDvs all stocks (USD)
EBITDA (TTM)
-102.04MUSDvs all stocks (USD)
Net Income (TTM)
-136.99MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-9.47%vs Biotechnology peers
Operating Cash Flow (TTM)
-114.55MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-74.85MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
81.36MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
5.80MUSDFY2025 · Dec 31, 2025Gross Profit
75.56MUSDFY2025 · Dec 31, 2025Operating Income
-107.21MUSDvs all stocks (USD)
Pre-tax Income
-141.61MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.01MUSDFY2025 · Dec 31, 2025Net Income
-142.62MUSDFY2025 · Dec 31, 2025EBIT
-89.97MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-74.31MUSDFY2025 · Dec 31, 2025Research & Development
104.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
79.93MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.81MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
51.63MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-142.62MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-147.97MUSDFY2025 · Dec 31, 2025Free Cash Flow
-148.36MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
261.34MUSDFY2025 · Dec 31, 2025Interest Paid
14.47MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-142.62MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.88MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.91MUSDFY2025 · Dec 31, 2025Other Non-cash Items
9.04MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.79MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-9.04MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.34MUSDFY2025 · Dec 31, 2025Capital Expenditures
395.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
395.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.51MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
84.77MUSDFY2025 · Dec 31, 2025Shares Outstanding
127.17MSharesUpdated Jul 17, 2026Float Shares
89.02MSharesUpdated Jul 17, 2026Shares Short
5.99MSharesUpdated Jul 17, 2026Short Ratio
1.79daysvs all stocks
Short % of Shares Outstanding
5.56%vs all stocks
% Held by Insiders
14.47%vs all stocks
% Held by Institutions
67.84%vs all stocks
Total Cash (MRQ)
231.01MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.82USDUpdated Jul 17, 2026Total Debt (MRQ)
436.26MUSDvs all stocks (USD)
Current Ratio (MRQ)
4.09xvs Biotechnology peers
Book Value per Share (MRQ)
-1.70USDUpdated Jul 17, 2026Total Assets
323.15MUSDvs all stocks (USD)
Total Current Assets
306.33MUSDFY2025 · Dec 31, 2025Total Liabilities
508.98MUSDFY2025 · Dec 31, 2025Total Non-current Assets
16.82MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
438.82MUSDFY2025 · Dec 31, 2025Total Current Liabilities
70.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
261.34MUSDFY2025 · Dec 31, 2025Accounts Receivable
29.12MUSDFY2025 · Dec 31, 2025Inventory
4.18MUSDFY2025 · Dec 31, 2025Accounts Payable
9.18MUSDFY2025 · Dec 31, 2025Short-term Debt
3.54MUSDFY2025 · Dec 31, 2025Other Current Liabilities
23.13MUSDFY2025 · Dec 31, 2025Long-term Debt
113.49MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
2.81MUSDFY2025 · Dec 31, 2025Common Stock (Book)
11.08MUSDFY2025 · Dec 31, 2025Retained Earnings
-1.64BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-185.83MUSDvs all stocks (USD)
Treasury Stock
205.00KUSDFY2025 · Dec 31, 202552-Week Low
0.7800USDUpdated Jul 17, 202652-Week High
4.98USDUpdated Jul 17, 202652-Week Change
-53.96%vs all stocks
Beta
1.88xvs all stocks
50-Day MA
2.14USDUpdated Jul 17, 2026200-Day MA
3.53USDUpdated Jul 17, 2026Avg 10-Day Volume
1.29MSharesUpdated Jul 17, 2026Avg 30-Day Volume
2.78MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-0.9700USDUpdated Jul 17, 2026Other Income / Expense
8.42MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.83Profit Margin: -1.73
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 2.47
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $171.71M, lower than 95% of all stocks globallySignificant
Market cap (USD): 171,708,063Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Asterasys Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NervGen Pharma Corp.
Tier 1ProductionApproval-Gated PipelineRule
Alector Inc.
Tier 1ProductionApproval-Gated PipelineRule
Journey Medical Corp
Tier 1ProductionApproval-Gated PipelineRule
MediWound Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Mycenax Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sensorion SA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Graphy Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Anika Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Carvana Co.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
TLB Co. Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Emergent BioSolutions Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown